KRAS and pancreatic neoplasm: Independently of the assay used, all assayed IQc compounds (2a, 2d, 3d, 3e), with the exception of 1, markedly affected the viability of cell lines harbouring mutated KRAS, namely the lung cancer cell line A594 (0.40 < IC50 < 1.45 μM), the pancreatic cancer cell lines MiaPaCa2 (1.98 < IC50 < 2.20 μM) and Panc-1 (0.22 < IC50 < 4.80 μM), and the colon cancer cell lines HCT116 (0.14 < IC50 < 3.46 μM) and SW620 (0.20 < IC50 < 4.74 μM).